Novel Adjuvant Therapy with Zinc Supplementation in Neonatal Respiratory Distress Syndrome / Mohamed Shawky Elfarargy, Ghada M Al-Ashmawy, Sally Abu-Risha, Haidy Khattab
Background: Neonatal respiratory distress syndrome (RDS) is a common dangerous chestproblem that is caused by a lack of surfactant. Aim: The aim of this study was to show the role of zinc as an adjuvant anti-inflammatory therapyin neonatal RDS. Objective: To study the effect of zinc supplementation in cases of neonatal RDS. Methods: A prospective randomized controlled trial (RCT) study was done on 90 neonates sufferingfrom respiratory distress (RD) who had been diagnosed as RDS. The included neonates wereclassified into two groups: group 1, which received Zinc (Zn) supplementation, and group 2, whichreceived a placebo. Down score, grades of RDS Malondialdehyde (MDA), Superoxide Dismutase(SOD) andInterleukin-8 (IL-8) were estimated on the 1st and 5th day in the presence of incubators. Results: There were statistically significant differences (SSD) in grades of RDS, Down score,MDA, SOD and IL-8 on the 5th day between group 1 and 2(p = 0.001), and between 1st and 5th dayin group 1 (p = 0.001) in the presence of an incubator. There was an SSD between groups 1 and 2in the duration of hospitalization (p = 0.001) and the number of cases that needed mechanical ventilation(MV) (p = 0.049). Conclusion: Zn supplementation is associated with clinical and laboratory improvement in casesof neonatal RDS. Recommendation: Zn supplementation for RDS neonates.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Endocrine, metabolic & immune disorders, drug targets - 21(2021), 12, Seite 7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Elfarargy, Mohamed Shawky [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (7 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011151471 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011151471 | ||
| 003 | DE-627 | ||
| 005 | 20231128081042.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011151471 | ||
| 035 | |a (KFL)prod_DARH_.3F36E5D6F0EBC331F1AA0B8C0CF075EB7FA1FB91 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Elfarargy, Mohamed Shawky |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel Adjuvant Therapy with Zinc Supplementation in Neonatal Respiratory Distress Syndrome |c Mohamed Shawky Elfarargy, Ghada M Al-Ashmawy, Sally Abu-Risha, Haidy Khattab |
| 264 | 1 | |c 2021 | |
| 300 | |a 1 Online-Ressource (7 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Neonatal respiratory distress syndrome (RDS) is a common dangerous chestproblem that is caused by a lack of surfactant. Aim: The aim of this study was to show the role of zinc as an adjuvant anti-inflammatory therapyin neonatal RDS. Objective: To study the effect of zinc supplementation in cases of neonatal RDS. Methods: A prospective randomized controlled trial (RCT) study was done on 90 neonates sufferingfrom respiratory distress (RD) who had been diagnosed as RDS. The included neonates wereclassified into two groups: group 1, which received Zinc (Zn) supplementation, and group 2, whichreceived a placebo. Down score, grades of RDS Malondialdehyde (MDA), Superoxide Dismutase(SOD) andInterleukin-8 (IL-8) were estimated on the 1st and 5th day in the presence of incubators. Results: There were statistically significant differences (SSD) in grades of RDS, Down score,MDA, SOD and IL-8 on the 5th day between group 1 and 2(p = 0.001), and between 1st and 5th dayin group 1 (p = 0.001) in the presence of an incubator. There was an SSD between groups 1 and 2in the duration of hospitalization (p = 0.001) and the number of cases that needed mechanical ventilation(MV) (p = 0.049). Conclusion: Zn supplementation is associated with clinical and laboratory improvement in casesof neonatal RDS. Recommendation: Zn supplementation for RDS neonates | ||
| 700 | 1 | |a Al-Ashmawy, Ghada M |e verfasserin |4 aut | |
| 700 | 1 | |a Abu-Risha, Sally |e verfasserin |4 aut | |
| 700 | 1 | |a Khattab, Haidy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine, metabolic & immune disorders, drug targets |d Sharjah : Bentham Science Publ., 2006 |g 21(2021), 12, Seite 7 |h Online-Ressource |w (DE-627)KFL000040738 |w (DE-600)2254157-3 |w (DE-576)273890999 |x 2212-3873 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:12 |g pages:7 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5303&volume=21&issue=12&spage=2253 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_02 | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 12 |h 7 | ||